Loading...
•
Mar 31, 2020
Curis Q1 2020 Earnings Report
Curis reported financial results for the first quarter ended March 31, 2020.
Key Takeaways
Curis reported a net loss of $9.7 million, or $0.28 per share, for the first quarter of 2020. Revenues for the quarter were $2.7 million, primarily from royalty revenues on Genentech and Roche's Erivedge sales. The company's cash, cash equivalents, and investments totaled $12.5 million as of March 31, 2020.
Advanced ongoing study for CA-4948.
Accomplished key licensing and financial objectives.
Implemented clinical and operational measures in response to the COVID-19 pandemic.
Expects to initiate a Phase 1 trial of CA-4948 in patients with AML and MDS in the second quarter of 2020.
Revenue by Segment
Forward Guidance
Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into the second half of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...